PRIMED acquired by INFLEXION

Inflexion agreed on 16 July 2026 to acquire Primed Group, the German maker of single-use medical consumables, from Paragon Partners, the DACH-focused private equity firm, in a deal valuing the company at an enterprise value of , an EV/EBITDA multiple of . The investment was made through Inflexion's Buyout Fund VI and remained subject to regulatory approvals. Paragon had bought the business at the end of October 2023. At the time of the deal, Primed employed more than 450 people and sold its MDR-certified products in over 70 countries to hospitals and care facilities. Its range covers devices used in tracheostomy and laryngectomy, wound drainage, thoracic surgery and stool management, alongside the HA2 sterilisation business. Chief executive Daniel Schiel said Inflexion shared the company's long-term vision and brought experience in supporting ambitious businesses through their next phase of growth. Inflexion planned to invest in Primed's core product range, accelerate product development, expand the sterilisation business and pursue acquisitions to strengthen its commercial presence and direct access to customers in key international markets. It brought in two healthcare executives to join the board: Wolfgang Suessle, former chief executive and president of Lohmann & Rauscher, and Justin Barnes, who has held senior roles in the medical device sector including chief executive of 30 Technology. The deal was Inflexion's sixth investment in the DACH region and its third in healthcare there. Clifford Chance advised Paragon Partners on the sale, while ARQIS acted as legal counsel to Inflexion.

It is worth noting that the fund Paragon took control of Primed through an LBO in 2023.